Trial
NCT06839872
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
Eli Lilly and Company
Condition
Chronic Lymphocytic Leukemia
Intervention
Pirtobrutinib
Why stopped
AstraZeneca has made the decision to cancel the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-05